萨库比特里尔/瓦尔沙坦在患有心力衰竭的全身性硬化症患者中的有效性:回顾性分析

相关实验视频

Updated: Sep 18, 2025

07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

Nouran Eshak¹, Mahmoud Abdelnabi², Jaxon Quillen³

¹Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.

Journal of clinical medicine

|June 26, 2025

概括

萨库比特里尔/瓦尔萨坦 (SV) 在全身性硬化症 (SSc) 患者中改善了心脏功能,这些患者患有心力衰竭和减少喷射率 (HFrEF). 治疗导致血压降低,NT-proBNP水平降低,左心室喷射率 (LVEF) 改善.

科学领域:

心脏病学心脏病学
类风湿病学类风湿病学
药理学药理学是指药理学的学科.

背景情况:

在全身性硬化症 (SSc) 中心脏参与显著影响预后和生存率.
减少喷射分数 (HFrEF) 的心力衰竭是SSc患者的一种严重并发症.
萨库比特里尔/瓦尔萨坦 (SV) 是一种血管激素受体非普利辛抑制剂,在管理HFrEF方面表现有前途.

研究的目的:

评估在患有全身性硬化症 (SSc) 和心力衰竭的患者中萨库比特里尔/瓦尔萨坦 (SV) 的疗效和安全性.
评估SV对心脏功能,临床结果和SSc患者HFrEF的实验室标记物的影响.

主要方法:

在2015年1月至2023年8月期间,对24名SSc患者进行 SV 治疗的回顾性分析.
临床表型,纵向数据分析,以及住院,死亡率,实验室标志物和心声回声检查结果的评估.
基线和随访数据的比较,包括血压,NT-proBNP和左心室喷射率 (LVEF).

主要成果:

治疗SV导致系统血压 (128~114mmHg) 和NT-proBNP水平 (15,130~5082 pg/mL) 显著降低.
在可用心声图的患者中,观察到左心室喷射率 (LVEF) 的显著改善 (40.3%至47.7%).
低血压是显著的副作用,导致16.7%的患者停止使用SV.

结论:

萨库比特里尔/瓦尔萨坦 (SV) 有效地改善了系统性硬化症 (SSc) 患者的心力衰竭与减少射出小部分 (HFrEF) 的心脏症状和功能.
脊髓炎对血压,心脏生物标志物和左心室喷射率 (LVEF) 产生有益影响.
需要进一步的前性研究来证实这些发现,并探索SV在其他SSc表现中的作用.

关键词:

心血管疾病的结果.心力衰竭与减少的喷射分数心力衰竭萨库比特里尔/瓦尔萨坦系统性硬化症系统性硬化症

相关概念视频

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

524

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

524

01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

01:22

Heart Failure Drugs: Diuretics

505

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

505

01:22

Heart Failure Drugs: β-Blockers

445

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

445